Renaissance Capital logo

Pre-IPO research available on Greenway Medical Technologies

February 1, 2012

Greenway Medical Technologies aims to modernize the doctor's appointment. The IT solutions provider for healthcare practices hopes to raise $80 million this week by offering 7 million shares at a price range of $11 to $13. Greenway plans to list on the New York Stock Exchange under the ticker symbol GWAY. J.P. Morgan, Morgan Stanley and William Blair are the lead underwriters on the deal, which is one of eight on the calendar this week.

By moving patient histories and practice management from paper-based systems to computers, Greenway's software allows physicians to have a more comprehensive view of patient records. Adoption rates have been aided by the HITECH Act, which offers $19 billion in incentives to providers. The market opportunity is estimated at $35 billion. Greenway currently serves approximately 1,800 small practices with a 95% retention rate.

Read more about Greenway's business, risks and outlook.


The performance of two healthcare technology IPOs last year was mixed. MedQuist Holdings (MEDH), which provides medical transcription services, is trading up 31% from its IPO price. Mobile drug reference app maker Epocrates (EPOC), which tried to move into the electronic health records space, is down 41%. Both companies went public in early February 2011.

We think investors will be pleased with Greenway's fundamentals. It addresses a large market opportunity, and government incentives are pushing customers to adopt. Its 95% retention rate indicates value, and its recurring revenue (45% of sales) provides visibility. Although there are concerns about competition and pricing pressure, the growing software company has a chance to stand out in a busy week for pricing activity.

For information on how to obtain our complete Pre-IPO research with rating and valuation model on Greenway, please contact Renaissance Capital.